Evangelismos S.A.
- Address
- lock Available on a paid plan
Evangelismos S.A. - Advanced Clinical Research Center
Evangelismos S.A. is a leading clinical research institution specializing in complex hematologic malignancies and innovative oncology therapeutics. The center demonstrates particular expertise in multiple myeloma research, conducting numerous Phase 3 trials evaluating cutting-edge treatments including CAR-T cell therapy, bispecific antibodies, and novel combination regimens for relapsed and refractory disease.
- Hematologic malignancies including multiple myeloma, chronic lymphocytic leukemia, and B-cell lymphomas
- Pulmonary vascular diseases, particularly pulmonary arterial hypertension with multiple therapeutic approaches
- Inflammatory and autoimmune conditions including Crohn's disease, ulcerative colitis, and lupus erythematosus
- Infectious diseases and cardiovascular disorders
The research center plays a pivotal role in evaluating next-generation immunotherapies and targeted agents across diverse therapeutic areas. Their portfolio includes advanced studies of novel mechanisms such as BTK inhibitors, BCMA-directed therapies, and bispecific T-cell engagers. The center's involvement in rare disease research extends to conditions like thrombotic thrombocytopenic purpura, congenital adrenal hyperplasia, and Cushing's syndrome. With expertise spanning from early-phase dose-finding studies to large-scale confirmatory trials, Evangelismos S.A. contributes significantly to the development of transformative treatments for patients with high unmet medical needs.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 199 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 193 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 33 by active trials.
- 1Merck Sharp & Dohme LLC9active
lock +32 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC12trials
lock +24 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Evangelismos S.A.
lock Showing 1 of 139 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 40-Week Randomized Study Evaluating the Efficacy and Safety of Weekly Insulin Icodec/Semaglutide Versus Daily Insulin Glargine in Type 2 Diabetes Patients | Novo Nordisk A/S | Phase III | Not Recruiting | Feb 2024 | Jun 2025 |
IMP list
lock Showing 1 of 199 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 19 | Unknown | 2017-12-14 | 2026-06-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.